Dihydroartemisinin
- Generic Name
- Dihydroartemisinin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H24O5
- CAS Number
- 71939-50-9
- Unique Ingredient Identifier
- 6A9O50735X
- Background
Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections . It was first authorized for market by the European Medicines Agency in October 2011 in combination with Piperaquine as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and stongly r...
- Indication
For the treatment of uncomplicated Plasmodium falciparum infection in adults, children, and infants aged 6 months and up weighing over 5 kg . Used in combination with Piperaquine.
- Associated Conditions
- Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Efficacy of Dihydroartemisinin for Treating PCOS
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06417099
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
- Target Recruit Count
- 50
- Registration Number
- NCT06036030
- Locations
- 🇮🇩
Manokwari Regional General Hospital, Manokwari, West Papua, Indonesia
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
- Target Recruit Count
- 36
- Registration Number
- NCT05829187
- Locations
- 🇮🇩
Kori Puskesmas, Tambolaka, East Nusa Tenggara, Indonesia
The Effect of Dihydroartemisinin in PCOS
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05465135
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.